Next 10 |
2024-07-26 14:13:09 ET More on Novo Nordisk Novo Nordisk: Better Buying Opportunities Ahead Novo Nordisk: Buy On Dips Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy Novo Nordisk wins EU backing for Wegovy label update Viking s...
2024-07-26 11:48:00 ET Summary Results from phase 3 RESILIENT study, using taldefgrobep alfa for the treatment of patients with spinal muscular atrophy, expected in the 2nd half of 2024. The global spinal muscular atrophy treatment market is projected to reach $8.4 billion by 2032...
2024-07-26 11:18:45 ET More on AbbVie AbbVie Inc. (ABBV) Q2 2024 Earnings Call Transcript AbbVie: Why I Sold My Shares At $175 AbbVie Q2 2024 Earnings Preview: Post Gonzalez Era Can Begin On Positive Note Cerevel gains as AbbVie says it expects deal to close ...
2024-07-26 10:12:18 ET Summary Novo Nordisk A/S has achieved a 20.8% annualized return over three decades, becoming Europe's largest company by market cap. The company efficiently managed the increased demand for obesity drugs, but faces intensifying competition as more players en...
2024-07-26 07:45:00 ET Over the last 18 months, the stock market has been incredibly generous to investors. Since January 2023, the S&P 500 has soared 45%, while the tech-heavy Nasdaq Composite has rocketed by 72%. Outside of the technology industry, investors have also foun...
2024-07-26 07:22:32 ET More on Biogen, BioArctic AB (publ), etc. Biogen's Diverse Drug Portfolio Faces Competitive Challenges In 2024 Biogen Stock: Cheapish, But With Few Growth Prospects Eisai: Margin Of Safety From Very Modest Penetration Expectations Bioge...
2024-07-25 19:06:06 ET It wasn't so long ago when Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) stocks were flying high thanks to their hotly popular weight loss drugs (Wegovy/Ozempic for Novo Nordisk and Zepbound/Mounjaro for Lilly). In the pharmaceutical industry,...
Lilly Confirms Date and Conference Call for Second-Quarter 2024 Financial Results Announcement PR Newswire INDIANAPOLIS , July 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2024 financial results on Aug. 8, 2024 ....
2024-07-25 08:40:31 ET Summary Eli Lilly's stock has surged 88.5% in the past year, driven by weight loss drugs. Approval of tirzepatide for weight management in China and the EU opens up new markets for the company. Despite strong growth potential, Eli Lilly's stock remains p...
2024-07-25 08:30:15 ET Palm Beach, FL – July 25, 2024 – The fibromyalgia treatment market has witnessed positive growth trends over the past few years. There is higher disease awareness due to growth in diagnosis rates and growing awareness and concern for this serious, debili...
News, Short Squeeze, Breakout and More Instantly...
2024-07-26 07:45:00 ET Over the last 18 months, the stock market has been incredibly generous to investors. Since January 2023, the S&P 500 has soared 45%, while the tech-heavy Nasdaq Composite has rocketed by 72%. Outside of the technology industry, investors have also foun...
2024-07-25 19:06:06 ET It wasn't so long ago when Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) stocks were flying high thanks to their hotly popular weight loss drugs (Wegovy/Ozempic for Novo Nordisk and Zepbound/Mounjaro for Lilly). In the pharmaceutical industry,...
Lilly Confirms Date and Conference Call for Second-Quarter 2024 Financial Results Announcement PR Newswire INDIANAPOLIS , July 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2024 financial results on Aug. 8, 2024 ....